Effect of antitumor therapy on microflora and oral mucosa in patients with malignant neoplasms

Abstract

The present article investigates the relationship between the microbiota of the oral cavity and oral mucositis induced by systemic antitumor therapy in patients with malignant neoplasms. This article highlights modern ideas about the composition of the normal microbiota of the oral cavity and its changes during chemotherapeutic treatment.

It has been shown that the normal oral microbiota includes representatives of such genera as Actinomyces, Corynebacterium, Fusobacterium, Leptotrichia, Neisseria, Prevotella, Streptococcus, and Veillonella. Moreover, it is emphasized that despite the existence of modern molecular genetic techniques and development of an oral microbiota database, determining the role of individual taxonomic units in oral homeostasis remains challenging.

Existing studies of changes in the qualitative and quantitative composition of oral microflora against the background of drug antitumor therapy have demonstrated that treatment is associated with significant changes in the microbiological landscape of the oral cavity. An increase was noted in the number of Gram-negative anaerobic opportunistic flora and a decrease in the representation of protective commensal flora. It has been demonstrated that the components of a bacterial cell can modulate the local reactions of a macroorganism through a system of Toll-like receptors while acting in different directions.

Several unresolved fundamental issues related to the role of oral microbiota in the pathogenesis of oral mucositis are highlighted.

Keywords

oral mucositis / oral microbiota / oral dysbiosis / systemic antitumor therapy / malignant neoplasms / chemotherapy

References

[1] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660

[2] Sung H., Ferlay J., Siegel R.L., et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries // CA Cancer J Clin. 2021. Vol. 71, N 3. P. 209–249. doi: 10.3322/caac.21660

[3] Kaprin AD, Starinskij VV, Shahzadova AO, editors. State of oncological care for the Russian population in 2022. Moscow: MNIOI im. P.A. Gercena — filial FGBU «NMIC radiologii» Minzdrava Rossii; 2022. 239 p. (In Russ).

[4] Состояние онкологической помощи населению России в 2022 году / под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. Москва : МНИОИ им. П.А. Герцена — филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2022. 239 с.

[5] Wilson BE, Jacob S, Yap ML, et al. Estimates of global chemotherapy demands and corresponding physician workforce requirements for 2018 and 2040: a population-based study. Lancet Oncol. 2019;20(6):769–780. Corrected and republished from: Lancet Oncol. 2019;20(7):e346. doi: 10.1016/S1470-2045(19)30163-9

[6] Wilson B.E., Jacob S., Yap M.L., et al. Estimates of global chemotherapy demands and corresponding physician workforce requirements for 2018 and 2040: a population-based study // Lancet Oncol. 2019. Vol. 20, N 6. P. 769–780. Corrected and republished from: Lancet Oncol. 2019. Vol. 20, N 7. P. e346. doi: 10.1016/S1470-2045(19)30163-9

[7] Kaprin AD, Starinskij VV, Shahzadova AO, editors. Malignant neoplasms in Russia in 2021 (morbidity and mortality). Moscow: MNIOI im. P.A. Gercena — filial FGBU «NMIC radiologii» Minzdrava Rossii, 2022. 252 p. (In Russ).

[8] Злокачественные новообразования в России в 2021 году (заболеваемость и смертность) / под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. Москва : МНИОИ им. П.А. Герцена — филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2022. 252 с.

[9] Semiglazova TJu, Beljak NP, Vladimirova LJu, et al. Practical recommendations for the treatment and prevention of mucositis. Malignant tumours (Zlokačestvennye opuholi). 2021;11(3s2-2):224–232. (In Russ). EDN: CRLBFQ doi: 10.18027 / 2224-5057-2021-11-3s2-51

[10] Семиглазова Т.Ю., Беляк Н.П., Владимирова Л.Ю., и др. Практические рекомендации по лечению и профилактике мукозитов // Злокачественные опухоли. 2021. Т. 11, № 3s2-2. С. 224–232. EDN: CRLBFQ doi: 10.18027/2224-5057-2021-11-3s2-51

[11] Basile D, Di Nardo P, Corvaja C, et al. Mucosal injury during anti-cancer treatment: from pathobiology to bedside. Cancers (Basel). 2019;11(6):857. doi: 10.3390/cancers11060857

[12] Basile D., Di Nardo P., Corvaja C., et al. Mucosal injury during anti-cancer treatment: from pathobiology to bedside // Cancers (Basel). 2019. Vol. 11, N 6. P. 857. doi: 10.3390/cancers11060857

[13] Sytov AV, Zuzov SA, Kukosh MJu, et al. Anorexia-cachexia syndrome in cancer patients. Malignant tumours (Zlokačestvennye opuholi). 2023;13(3s2-2):143–147. (In Russ). EDN: DMIEGE doi: 10.18027/2224-5057-2023-13-3s2-2-143-147

[14] Сытов А.В., Зузов С.А., Кукош М.Ю., и др. Синдром анорексии-кахексии у онкологических больных // Злокачественные опухоли. 2023. Т. 13, № 3s2-2. С. 143–147. EDN: DMIEGE doi: 10.18027/2224-5057-2023-13-3s2-2-143-147

[15] Gameeva EV, Stepanova AM, Tkachenko GA. Comprehensive rehabilitation of cancer patients: a review. Journal of Modern Oncology. 2022;24(1):89–96. EDN: UWXJQI doi: 10.26442/18151434.2022.1.201476

[16] Гамеева Е.В., Степанова А.М., Ткаченко Г.А., и др. Комплексная реабилитация онкологических пациентов // Современная онкология. 2022. Т. 24, № 1. С. 89–96. EDN: UWXJQI doi: 10.26442/18151434.2022.1.201476

[17] Sytov AV, Zuzov SA, Kukosh MJu, et al. Practical recommendations on nutritional support for cancer patients. Malignant tumours (Zlokačestvennye opuholi). 2021;11(3s2-2):114–122. (In Russ). EDN: DLDCIT doi: 10.18027/2224-5057-2021-11-3s2-43

[18] Сытов А.В., Зузов С.А., Кукош М.Ю., и др. Практические рекомендации по нутритивной поддержке онкологических больных // Злокачественные опухоли. 2021. Т. 11, №3s2-2. С. 114–122. doi: 10.18027/2224-5057-2021-11-3s2-43

[19] Marcussen M, Sønderkær M, Bødker JS, et al. Oral mucosa tissue gene expression profiling before, during, and after radiation therapy for tonsil squamous cell carcinoma. PLoS One. 2018;13(1):e0190709. doi: 10.1371/journal.pone.0190709

[20] Marcussen M., Sønderkær M., Bødker J.S., et al. Oral mucosa tissue gene expression profiling before, during, and after radiation therapy for tonsil squamous cell carcinoma // PLoS One. 2018. Vol. 13, N 1. P. e0190709. doi: 10.1371/journal.pone.0190709

[21] Komogortseva VE, Makeeva IM, Reshetov IV, et al. Use of the hygienic protocol for prevention of complications from the oral cavity organs and tissues in cancer patients during chemotherapy. Medical & Pharmaceutical Journal Pulse. 2023;25(5):101–106. EDN: RGRVFD doi: 10.26787/nydha-2686-6838-2023-25-5-101-106

[22] Комогорцева В.Е., Макеева И.М., Решетов И.В., и др. Применение гигиенического протокола для предупреждения развития осложнений со стороны органов и тканей полости рта у онкологических пациентов в период химиотерапии // Медико-фармацевтический журнал Пульс. 2023. Т. 25, № 5. С. 101–106.

[23] Mougeot JC, Stevens CB, Morton DS, et al. Oral microbiome and cancer therapy-induced oral mucositis. J Natl Cancer Inst Monogr. 2019;2019(53):lgz002. doi: 10.1093/jncimonographs/lgz002

[24] Mougeot J.C., Stevens C.B., Morton D.S., et al. Oral microbiome and cancer therapy-induced oral mucositis // J Natl Cancer Inst Monogr. 2019. Vol. 2019, N 53. P. lgz002. doi: 10.1093/jncimonographs/lgz002

[25] Stringer AM, Logan RM. The role of oral flora in the development of chemotherapy-induced oral mucositis. J Oral Pathol Med. 2015;44(2):81–87. doi: 10.1111/jop.12152

[26] Stringer A.M., Logan R.M. The role of oral flora in the development of chemotherapy-induced oral mucositis // J Oral Pathol Med. 2015. Vol. 44, N 2. P. 81–87. doi: 10.1111/jop.12152

[27] Turnbaugh PJ, Ley RE, Hamady M, et al. The human microbiome project. Nature. 2007;449(7164):804–810. doi: 10.1038/nature06244

[28] Turnbaugh P.J., Ley R.E., Hamady M., et al. The human microbiome project // Nature. 2007. Vol. 449, N 7164. P. 804–810. doi: 10.1038/nature06244

[29] Grigor’evskaja ZV, Tereshhenko IV, Kazimov AJe, et al. Oral microbiota and its importance in the genesis of oropharyngeal cancer. Malignant tumours (Zlokačestvennye opuholi). 2020;10(3S1):54–59. EDN: ZJBYGE doi: 10.18027/2224-5057-2020-10-3s1-54-59

[30] Григорьевская З.В., Терещенко И.В., Казимов А.Э., и др. Микробиота полости рта и ее значение в генезе рака орофарингеальной зоны // Злокачественные опухоли. 2020. Т. 10, № 3S1. С. 54–59. EDN: ZJBYGE doi: 10.18027/2224-5057-2020-10-3s1-54-59

[31] Kaybysheva VO, Zharova ME, Filimendikova KYu, Nikonov EL. Human microbiome: age-related changes and functions. Russian Journal of Evidence-Based Gastroenterology. 2020;9(2):42–55. EDN: YKXBBQ doi: 10.17116/dokgastro2020902142

[32] Кайбышева В.О., Жарова М.Е., Филимендикова К.Ю., Никонов Е.Л. Микробиом человека: возрастные изменения и функции // Доказательная гастроэнтерология. 2020. Т. 9, № 2. С. 42–55. EDN: YKXBBQ doi: 10.17116/dokgastro2020902142

[33] Nikonov EL, Popova EN, editors. Microbiota. Moscow: Izdatel’stvo Media Sfera; 2019. 255 p. (In Russ). EDN: XDPQAO

[34] Микробиота / под ред. Е.Л. Никонова, Е.Н. Поповой. Москва : Издательство Медиа Сфера, 2019. 255 с. EDN: XDPQAO

[35] Lamont RJ, Koo H, Hajishengallis G. The oral microbiota: dynamic communities and host interactions. Nat Rev Microbiol. 2018;16(12):745–759. doi: 10.1038/s41579-018-0089-x

[36] Lamont R.J., Koo H., Hajishengallis G. The oral microbiota: dynamic communities and host interactions // Nat Rev Microbiol. 2018. Vol. 16, N 2. P. 745–759. doi: 10.1038/s41579-018-0089-x

[37] Ghannoum MA, Jurevic RJ, Mukherjee PK, et al. Characterization of the oral fungal microbiome (mycobiome) in healthy individuals. PLoS Pathog. 2010;6(1):e1000713. doi: 10.1371/journal.ppat.1000713

[38] Ghannoum M.A., Jurevic R.J., Mukherjee P.K., et al. Characterization of the oral fungal microbiome (mycobiome) in healthy individuals // PLoS Pathog. 2010. Vol. 6, N 1. P. e1000713. doi: 10.1371/journal.ppat.1000713

[39] van der Beek MT, Laheij AM, Raber-Durlacher JE, et al. Viral loads and antiviral resistance of herpesviruses and oral ulcerations in hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2012;47(9):1222–1228. doi: 10.1038/bmt.2012.2

[40] van der Beek M.T., Laheij A.M., Raber-Durlacher J.E., et al. Viral loads and antiviral resistance of herpesviruses and oral ulcerations in hematopoietic stem cell transplant recipients // Bone Marrow Transplant. 2012. Vol. 47, N 9. P. 1222–1228. doi: 10.1038/bmt.2012.2

[41] Bagirova NS, Dmitrieva NV, Petukhova IN. Mycobiota as part microbiota: features methods of studying at present. Problems of Biological, Medical and Pharmaceutical Chemistry. 2019;22(11):3–8. EDN: JYAPXB

[42] Багирова Н.С., Дмитриева Н.В., Петухова И.Н., и др. Микобиота как часть микробиоты: особенности методов изучения на современном этапе // Вопросы биологической, медицинской и фармацевтической химии. 2019. Т. 22, № 11. С. 3–8. EDN: JYAPXB

[43] Grigoriev SS, Bushueva EYu, Sablina SN. Clinical and laboratory approaches to the study of the correction of the microbiota of the oral cavity. Ural’skij medicinskij zhurnal. 2020;(9):24–33. EDN: CRRRXM doi: 10.25694/URMJ.2020.09.07

[44] Григорьев С.С., Бушуева Е.Ю., Саблина С.Н. Клинико-лабораторные подходы к изучению коррекции микробиоты полости рта // Уральский медицинский журнал. 2020. № 9. С. 24–33. EDN: CRRRXM doi: 10.25694/URMJ.2020.09.07

[45] Fiori B, D’Inzeo T, Di Florio V, et al. Performance of two resin-containing blood culture media in detection of bloodstream infections and in direct matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) broth assays for isolate identification: clinical comparison of the BacT/Alert Plus and Bactec Plus systems. J Clin Microbiol. 2014;52(10):3558–3567. doi: 10.1128/JCM.01171-14

[46] Fiori B., D’Inzeo T., Di Florio V., et al. Performance of two resin-containing blood culture media in detection of bloodstream infections and in direct matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) broth assays for isolate identification: clinical comparison of the BacT/Alert Plus and Bactec Plus systems // J Clin Microbiol. 2014. Vol. 52, N 10. P. 3558–3567. doi: 10.1128/JCM.01171-14

[47] Paster BJ, Boches SK, Galvin JL, et al. Bacterial diversity in human subgingival plaque. J Bacteriol. 2001;183(12):3770–3783. doi: 10.1128/JB.183.12.3770-3783.2001

[48] Paster B.J., Boches S.K., Galvin J.L., et al. Bacterial diversity in human subgingival plaque // J Bacteriol. 2001. Vol. 183, N 12. P. 3770–3783. doi: 10.1128/JB.183.12.3770-3783.2001

[49] Aas JA, Paster BJ, Stokes LN, et al. Defining the normal bacterial flora of the oral cavity. J Clin Microbiol. 2005;43(11):5721–5732. doi: 10.1128/JCM.43.11.5721-5732.2005

[50] Aas J.A., Paster B.J., Stokes L.N., et al. Defining the normal bacterial flora of the oral cavity // J Clin Microbiol. 2005. Vol. 43, N 11. P. 5721–5732. doi: 10.1128/JCM.43.11.5721-5732.2005

[51] Keijser BJ, Zaura E, Huse SM, et al. Pyrosequencing analysis of the oral microflora of healthy adults. J Dent Res. 2008;87(11):1016–1020. doi: 10.1177/154405910808701104

[52] Keijser B.J., Zaura E., Huse S.M., et al. Pyrosequencing analysis of the oral microflora of healthy adults // J Dent Res. 2008. Vol. 87, N 11. P. 1016–1020. doi: 10.1177/154405910808701104

[53] Bik EM, Long CD, Armitage GC, et al. Bacterial diversity in the oral cavity of 10 healthy individuals. ISME J. 2010;4(8):962–974. doi: 10.1038/ismej.2010.30

[54] Bik E.M., Long C.D., Armitage G.C., et al. Bacterial diversity in the oral cavity of 10 healthy individuals // ISME J. 2010. Vol. 4, N 8. P. 962–974. doi: 10.1038/ismej.2010.30

[55] Zaura E, Keijser BJ, Huse SM, Crielaard W. Defining the healthy “core microbiome” of oral microbial communities. BMC Microbiol. 2009;9:259. doi: 10.1186/1471-2180-9-259

[56] Zaura E., Keijser B.J., Huse S.M., Crielaard W. Defining the healthy “core microbiome” of oral microbial communities // BMC Microbiol. 2009. Vol. 9. P. 259. doi: 10.1186/1471-2180-9-259

[57] https://v2.homd.org [Internet]. Expanded Human Oral Microbiome Database (eHOMD). Available from: https://v2.homd.org

[58] https://v2.homd.org [Internet]. Expanded Human Oral Microbiome Database (eHOMD). Режим доступа: https://v2.homd.org

[59] Zaura E, Nicu EA, Krom BP, Keijser BJ. Acquiring and maintaining a normal oral microbiome: current perspective. Front Cell Infect Microbiol. 2014;4:85. doi: 10.3389/fcimb.2014.00085

[60] Zaura E., Nicu E.A., Krom B.P., Keijser B.J. Acquiring and maintaining a normal oral microbiome: current perspective // Front Cell Infect Microbiol. 2014. Vol. 4. P. 85. doi: 10.3389/fcimb.2014.00085

[61] Dewhirst FE, Chen T, Izard J, et al. The human oral microbiome. J Bacteriol. 2010;192(19):5002–5017. doi: 10.1128/JB.00542-10

[62] Dewhirst F.E., Chen T., Izard J., et al. The human oral microbiome // J Bacteriol. 2010. Vol. 192, N 19. P. 5002–5017. doi: 10.1128/JB.00542-10

[63] Paster BJ, Boches SK, Galvin JL, et al. Bacterial diversity in human subgingival plaque. J Bacteriol. 2001;183(12):3770–3783. doi: 10.1128/JB.183.12.3770-3783.2001

[64] Paster B.J., Boches S.K., Galvin J.L., et al. Bacterial diversity in human subgingival plaque // J Bacteriol. 2001. Vol. 183, N 12. P. 3770–3783. doi: 10.1128/JB.183.12.3770-3783.2001

[65] Trjakin AA, Besova NS, Volkov NM, et al. General principles of antitumor drug therapy. Malignant tumours (Zlokačestvennye opuholi). 2023;13(3s2-1): 28–41. EDN: TSJQVU doi: 10.18027/2224-5057-2023-13-3s2-1-28-41

[66] Трякин А.А., Бесова Н.С., Волков Н.М., и др. Общие принципы проведения противоопухолевой лекарственной терапии // Злокачественные опухоли. 2023. Т. 13, № 3s2-1. С. 28–41. EDN: TSJQVU doi: 10.18027/2224-5057-2023-13-3s2-1-28-41

[67] Perales-Puchalt A, Perez-Sanz J, Payne KK, et al. Frontline science: microbiota reconstitution restores intestinal integrity after cisplatin therapy. J Leukoc Biol. 2018;103(5):799–805. doi: 10.1002/JLB.5HI1117-446RR

[68] Perales-Puchalt A., Perez-Sanz J., Payne K.K., et al. Frontline science: microbiota reconstitution restores intestinal integrity after cisplatin therapy // J Leukoc Biol. 2018. Vol. 103, N 5. P. 799–805. doi: 10.1002/JLB.5HI1117-446RR

[69] Napeñas JJ, Brennan MT, Bahrani-Mougeot FK, et al. Relationship between mucositis and changes in oral microflora during cancer chemotherapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;103(1):48–59. doi: 10.1016/j.tripleo.2005.12.016

[70] Napeñas J.J., Brennan M.T., Bahrani-Mougeot F.K., et al. Relationship between mucositis and changes in oral microflora during cancer chemotherapy // Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007. Vol. 103, N 1. P. 48–59. doi: 10.1016/j.tripleo.2005.12.016

[71] Jensen SB, Mouridsen HT, Reibel J, et al. Adjuvant chemotherapy in breast cancer patients induces temporary salivary gland hypofunction. Oral Oncol. 2008;44(2):162–173. doi: 10.1016/j.oraloncology.2007.01.015

[72] Jensen S.B., Mouridsen H.T., Reibel J., et al. Adjuvant chemotherapy in breast cancer patients induces temporary salivary gland hypofunction // Oral Oncol. 2008. Vol. 44, N 2. P. 162–173. doi: 10.1016/j.oraloncology.2007.01.015

[73] Bagirova NS, Petukhova IN, Grigorievskaya ZV. Oral microbiota in patients with oropharyngeal cancer with an emphasis on Сandida. Head and Neck Tumors. 2022;12(3):71–85. EDN: SJRVDH doi: 10.17650/2222-1468-2022-12-3-71-85

[74] Багирова Н.С., Петухова И.Н., Григорьевская З.В., и др. Микробиота полости рта у больных раком орофарингеальной области с акцентом на Candida spp // Опухоли головы и шеи. 2022. Т. 12, № 3. С. 71–85. EDN: SJRVDH doi: 10.17650/2222-1468-2022-12-3-71-85

[75] Maier L, Pruteanu M, Kuhn M, et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018;555(7698):623–628. doi: 10.1038/nature25979

[76] Maier L., Pruteanu M., Kuhn M., et al. Extensive impact of non-antibiotic drugs on human gut bacteria // Nature. 2018. Vol. 555, N 7698. P. 623–628. doi: 10.1038/nature25979

[77] Hong BY, Sobue T, Choquette L, et al. Chemotherapy-induced oral mucositis is associated with detrimental bacterial dysbiosis. Microbiome. 2019;7(1):66. doi: 10.1186/s40168-019-0679-5

[78] Hong B.Y., Sobue T., Choquette L., et al. Chemotherapy-induced oral mucositis is associated with detrimental bacterial dysbiosis // Microbiome. 2019. Vol. 7, N 1. P. 66. doi: 10.1186/s40168-019-0679-5

[79] Klymiuk I, Bilgilier C, Mahnert A, et al. Chemotherapy-associated oral microbiome changes in breast cancer patients. Front Oncol. 2022;12:949071. doi: 10.3389/fonc.2022.949071

[80] Klymiuk I., Bilgilier C., Mahnert A., et al. Chemotherapy-associated oral microbiome changes in breast cancer patients // Front Oncol. 2022. Vol. 12. P. 949071. doi: 10.3389/fonc.2022.949071

[81] Zawadzki PJ, Perkowski K, Padzik M, et al. Examination of oral microbiota diversity in adults and older adults as an approach to prevent spread of risk factors for human infections. BioMed Res Int. 2017;2017:8106491. doi: 10.1155/2017/8106491

[82] Zawadzki P.J., Perkowski K., Padzik M., et al. Examination of oral microbiota diversity in adults and older adults as an approach to prevent spread of risk factors for human infections // BioMed Res Int. 2017. Vol. 2017. P. 8106491. doi: 10.1155/2017/8106491

[83] Eriksson K, Lundmark A, Delgado LF, et al. Salivary microbiota and host-inflammatory responses in periodontitis affected individuals with and without rheumatoid arthritis. Front Cell Infect Microbiol. 2022;12:841139. doi: 10.3389/fcimb.2022.841139

[84] Eriksson K., Lundmark A., Delgado L.F., et al. Salivary microbiota and host-inflammatory responses in periodontitis affected individuals with and without rheumatoid arthritis // Front Cell Infect Microbiol. 2022. Vol. 12. P. 841139. doi: 10.3389/fcimb.2022.841139

[85] Könönen E, Gursoy UK. Oral Prevotella species and their connection to events of clinical relevance in gastrointestinal and respiratory tracts. Front Microbiol. 2022;12:798763. doi: 10.3389/fmicb.2021.798763

[86] Könönen E., Gursoy U.K. Oral Prevotella species and their connection to events of clinical relevance in gastrointestinal and respiratory tracts // Front Microbiol. 2022. Vol. 12. P. 798763. doi: 10.3389/fmicb.2021.798763

[87] Zupancic K, Kriksic V, Kovacevic I, Kovacevic D. Influence of oral probiotic streptococcus salivarius K12 on ear and oral cavity health in humans: Systematic review. Probiotics Antimicrob Proteins. 2017;9(2):102–110. doi: 10.1007/s12602-017-9261-2

[88] Zupancic K., Kriksic V., Kovacevic I., Kovacevic D. Influence of oral probiotic streptococcus salivarius K12 on ear and oral cavity health in humans: systematic review // Probiotics Antimicrob Proteins. 2017. Vol. 9, N 2. P. 102–110. doi: 10.1007/s12602-017-9261-2

[89] Rodríguez-Fuentes ME, Pérez-Sayáns M, Chauca-Bajaña LA, et al. Oral microbiome and systemic antineoplastics in cancer treatment: a systematic review. Med Oral Patol Oral Cir Bucal. 2022;27(3):e248-e256. doi: 10.4317/medoral.25121

[90] Rodríguez-Fuentes M.E., Pérez-Sayáns M., Chauca-Bajaña L.A., et al. Oral microbiome and systemic antineoplastics in cancer treatment: a systematic review // Med Oral Patol Oral Cir Bucal. 2022. Vol. 27, N 3. P. e248–e256. doi: 10.4317/medoral.25121

RIGHTS & PERMISSIONS

Eco-Vector